The first-in-class SFK ‘OFF’ inhibitor NXP900 suppresses YAP signaling and demonstrates tumor growth suppression in cholangiocarcinoma

PURPOSE: Cholangiocarcinoma (CCA) is an aggressive malignancy with limited targeted therapeutic options and few validated strategies for molecular patient stratification. Src family kinases (SFKs) and YAP signaling contribute to CCA progression, but prior approaches to therapeutically target this axis have shown limited efficacy. Here, we evaluate the preclinical therapeutic potential of NXP900, a first-in-class SFK 'OFF' inhibitor, in CCA. EXPERIMENTAL DESIGN: The antitumor activity of NXP900 was assessed across CCA cell lines, syngeneic murine models, and patient-derived xenografts (PDXs). Mechanistic studies examined the impact of SFK 'OFF' inhibition on YAP signaling. Integrated transcriptomic and proteomic analyses were used to identify molecular features associated with response and resistance. RESULTS: NXP900 demonstrated decreased tumor cell viability in CCA cell lines and significant tumor growth suppression in PDX models. SFK 'OFF' inhibition suppressed YAP signaling through dual mechanisms involving inhibition of YAP Y357 phosphorylation and activation of Hippo pathway signaling. NXP900 enhanced the efficacy of gemcitabine and cisplatin, supporting its potential use in combination regimens. Multiomic analyses identified enrichment of sensitivity to NXP900 in IDH-mutant CCA models, defining a clinically actionable molecular subset. In addition, resistance to SFK 'OFF' inhibition was associated with activation of an IL13RA2-AKT signaling axis, which was pharmacologically targetable, providing a rational framework for combination strategies. CONCLUSIONS: These findings establish SFK 'OFF' inhibition with NXP900 as a promising therapeutic strategy in CCA and support biomarker-guided clinical evaluation, including in molecularly defined patient subsets and in combination with standard chemotherapy.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-11-20
DOI
https://doi.org/10.1158/1078-0432.ccr-26-0849
Primary Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The first-in-class SFK ‘OFF’ inhibitor NXP900 suppresses YAP signaling and demonstrates tumor growth suppression in cholangiocarcinoma

Dong‐Gi Mun, Gregory James Gores, Meina Cai, Sumera Irie Ilyas et al.
5 links
Clinical Cancer Research
Cholangiocarcinoma and Gallbladder Cancer Studies
article

The first-in-class SFK ‘OFF’ inhibitor NXP900 suppresses YAP signaling and demonstrates tumor growth suppression in cholangiocarcinoma

Dong‐Gi Mun, Gregory James Gores, Meina Cai, Sumera Irie Ilyas, Enis Özmert, Mitesh J. Borad, Jack W. Sample, Akhilesh Pandey, Mark Joseph Truty, Aushinie M. Abeynayake, Danielle Marie Carlson, Rory L. Smoot, Erik Jessen, Jennifer L. Tomlinson, Amro M. Abdelrahman, Hendrien Kuipers, Caitlin B. Conboy, Binbin Li, Nathan W. Werneburg
article en

Abstract

PURPOSE: Cholangiocarcinoma (CCA) is an aggressive malignancy with limited targeted therapeutic options and few validated strategies for molecular patient stratification. Src family kinases (SFKs) and YAP signaling contribute to CCA progression, but prior approaches to therapeutically target this axis have shown limited efficacy. Here, we evaluate the preclinical therapeutic potential of NXP900, a first-in-class SFK 'OFF' inhibitor, in CCA. EXPERIMENTAL DESIGN: The antitumor activity of NXP900 was assessed across CCA cell lines, syngeneic murine models, and patient-derived xenografts (PDXs). Mechanistic studies examined the impact of SFK 'OFF' inhibition on YAP signaling. Integrated transcriptomic and proteomic analyses were used to identify molecular features associated with response and resistance. RESULTS: NXP900 demonstrated decreased tumor cell viability in CCA cell lines and significant tumor growth suppression in PDX models. SFK 'OFF' inhibition suppressed YAP signaling through dual mechanisms involving inhibition of YAP Y357 phosphorylation and activation of Hippo pathway signaling. NXP900 enhanced the efficacy of gemcitabine and cisplatin, supporting its potential use in combination regimens. Multiomic analyses identified enrichment of sensitivity to NXP900 in IDH-mutant CCA models, defining a clinically actionable molecular subset. In addition, resistance to SFK 'OFF' inhibition was associated with activation of an IL13RA2-AKT signaling axis, which was pharmacologically targetable, providing a rational framework for combination strategies. CONCLUSIONS: These findings establish SFK 'OFF' inhibition with NXP900 as a promising therapeutic strategy in CCA and support biomarker-guided clinical evaluation, including in molecularly defined patient subsets and in combination with standard chemotherapy.

Clinical Cancer Research
Mayo Clinic (US), Mayo Clinic in Arizona (US)
Good health and well-being
Cholangiocarcinoma and Gallbladder Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon